im a materials engineer. i work with hollow mesoporous silica and dissolving microneedles as a drug delivery system for cancer specially skin cancer. im mostly interested in bio materials and drug delivery. i want to publish a paper in q1 or q2 with decent impact factor but i dont want to do lab work any more and i dont have any data. i want to publish a paper thats purely computational. in fields of machine learning and simulation and other things that are purely computational. i need a q1 or at worst a q2 paper in a good journal. i need to know the research gaps i can use to find good topics for my use case and the quality i need

Computational research directions for your microneedle–silica cancer-delivery background

Bottom line

A fully computational paper is a plausible direction, but Q1/Q2 publication cannot be promised, especially without new experimental data. The strongest route is not to apply a fashionable ML algorithm to a small table. It is to build a transparent, literature-grounded computational study that answers a consequential delivery question, compares against existing data, reports uncertainty, and is reproducible.

For your background, the most coherent proposed topic is a multiscale, uncertainty-aware model of dissolving microneedle delivery of drug-loaded hollow mesoporous silica particles to a skin tumor, with an open, literature-extracted benchmark dataset as its foundation. This connects your materials knowledge to mechanistic transport, simulation, and optional machine learning. It is also ambitious: before committing, you need to establish that sufficient published numerical data exist to parameterize and test it. In the full-text material available for this answer, I found evidence that microneedle models have important limitations, but I could not establish that a specific dissolving-microneedle/hollow-mesoporous-silica/melanoma computational gap is novel or still unaddressed. Treat that combination as a promising hypothesis to verify, not a confirmed gap.

What the available full text supports—and what it does not

A 2020 review of microneedle simulation reports that modeling was a small part of the microneedle literature it surveyed at the time, and identifies several limitations: many models treat a single needle rather than array-level behavior; some omit skin deformation and time-varying contact conditions; and the authors judged that sufficiently accurate, robust models for practical or manufacturing use were still lacking. It also describes a need for more in vivo and in vitro information to resolve needle–skin interactions and drug diffusion.(Yadav, 2020) (Yadav, 2020) (Yadav, 2020) These observations support research on better-integrated and more testable models. Because this is a 2020 review, use it as evidence for the limitations it identified, not as a current census of the field.

A 2025 in-silico study models hollow-needle delivery of verapamil using viscoelastic skin, interstitial flow, metabolism, and reversible saturable binding, and reports that predicted delivery depends on needle geometry and injection velocity.(Bhuimali, 2025) (Bhuimali, 2025) This shows that mechanistic modeling of microneedle delivery can incorporate coupled tissue and drug processes. It is not a study of dissolving needles, mesoporous silica, melanoma, or a validating benchmark for those systems.

So the defensible research opening from the evidence presently available is model integration, realism, and validation, not a categorical claim that no one has modeled your exact system. The search was restricted in practice to full text already accessible, and only two relevant full-text papers were available in the retrieved set. The PDFs requested for additional coverage may change the gap assessment. Do not write “the first” or “no previous study” until you have completed a broader, current search and checked the relevant full texts.

Ranked directions

1. Best fit: a mechanistic digital twin for dissolving microneedle delivery of mesoporous-silica drug carriers to a skin tumor

Research question (proposed): Under what combinations of patch geometry, polymer dissolution, particle loading/release, skin transport properties, and tumor depth does a dissolving microneedle patch maximize tumor-localized exposure while limiting drug escape into systemic compartments?

Why it is promising: The review identifies array-level effects, skin deformation, changing contact, formulation properties, and robust prediction as important modeling challenges.(Yadav, 2020) The newer hollow-needle model illustrates how tissue mechanics, interstitial flow, metabolism, and binding can materially affect predicted tissue and blood concentrations.(Bhuimali, 2025) A model that explicitly joins the dissolving patch, carrier release, skin layers, and tumor region could therefore address a clinically relevant integration problem. That specific integration remains a proposed gap; its novelty is not established by the two full texts reviewed here.

Computational scope: Start with a tractable two-dimensional axisymmetric or representative-array model rather than an elaborate 3-D “digital twin.” Couple (i) water uptake and polymer dissolution, (ii) drug release from the silica carrier as a parameterized process, (iii) diffusion and reversible partitioning through skin layers, (iv) tumor uptake or retention as a separate compartment, and (v) systemic loss as an output compartment. Use finite elements or finite volumes for transport, with a reduced-order model for parameter sweeps. Include needle-array geometry only if available data can inform its effect. Do not claim atomistic detail is necessary: molecular dynamics is only useful if it answers a defined materials question, such as relative drug–surface affinity, and its outputs can be connected defensibly to macroscopic release parameters.

Inputs and data plan: Extract ranges—not unjustified single “true” values—from full-text publications for needle dimensions, polymer dissolution or swelling, carrier size and loading, release curves, skin-layer thicknesses, diffusivities or permeabilities, and tumor-uptake parameters. Preserve each source, unit, experimental condition, and uncertainty. If a parameter is missing, use a sensitivity-informed range and label it as assumed; do not silently fill gaps with a convenient value. Include several published drugs or carrier systems only where measurements are comparable.

Analysis: First verify numerical convergence and mass conservation. Then calibrate only to a subset of published release/transport observations and test predictions against held-out studies or conditions. Use global sensitivity analysis to identify which inputs control tumor-to-skin exposure and tumor-to-systemic exposure. Propagate parameter uncertainty and report prediction intervals. Compare at least one simplified model against the integrated model to show whether added biological/material complexity improves out-of-sample prediction rather than merely adding parameters.

What makes this publishable rather than a simulation exercise: A reusable code repository, parameter and data table with provenance, a clear validation split, uncertainty analysis, and a result that changes a design decision—for example, a robust region of the design space rather than one nominal optimum. The crucial feasibility test is whether the literature contains enough quantitative measurements for calibration and genuinely independent testing. If there are no suitable external data, this should become a transparent exploratory model, not a claim of predictive performance.

2. More feasible: a curated benchmark and physics-informed ML study of microneedle release/transport

Research question (proposed): Can physics-informed or hybrid ML predict drug release or skin deposition across microneedle formulations better than standard empirical models when evaluation is split by publication or formulation family?

This route may be more realistic without lab access if enough published numerical observations can be extracted. The review discusses a need for more reliable prediction and notes that model inputs span needle geometry, materials, skin properties, and drug/formulation behavior.(Yadav, 2020) (Yadav, 2020) But the accessible full texts do not establish a mature public dataset or a specific ML gap. You must first conduct a systematic search and a data-feasibility audit.

Build the dataset before selecting algorithms. Define one primary outcome, such as cumulative released fraction at a stated time, release half-time, skin deposition, or permeation flux. Do not mix these endpoints into one target. Create a data dictionary and capture units, time points, drug, carrier, polymer, needle type, array geometry, test medium, skin model, temperature, and study identifier. Record missingness and whether a value was digitized from a plot. Digitized values should be checked independently and marked as lower-confidence than tabulated values.

Avoid data leakage. Randomly splitting individual time points from the same release curve between training and test sets would make performance look better than it is. Keep all observations from a paper, formulation, or experimental series together in the same split. Prefer leave-one-study-out or grouped cross-validation, plus an external holdout if possible. Compare simple baselines (for example, a mechanistic release equation or regularized regression) with tree-based and physics-informed/hybrid models. Given likely small and heterogeneous data, emphasize uncertainty and calibration, not only a headline R².

Potential contribution: The value may lie in the cleaned, annotated dataset and rigorous cross-study evaluation more than in a novel neural network. If the dataset is too small or inconsistent, pivot to a systematic evidence map plus a mechanistic meta-model rather than presenting an underpowered ML comparison as AI innovation.

3. High-materials relevance, higher risk: molecular simulation of drug–silica interactions linked to release

Research question (proposed): How do silica surface chemistry, pore size, hydration, and drug ionization state affect adsorption and desorption trends, and can those trends explain published differences in release profiles from mesoporous silica carriers?

This leverages your hollow mesoporous silica expertise, but it is not yet supported as a verified gap by the available full texts: neither accessible paper evaluates mesoporous-silica carriers. A computational-only paper based on molecular dynamics or density-functional theory could be publishable if it tests a specific materials hypothesis and validates calculated quantities against independent published measurements. It is much less convincing if it reports binding energies for a few arbitrarily selected drug/surface combinations with no link to experimentally observed loading or release.

A credible design would choose a narrow, literature-supported drug–surface system; specify realistic surface hydroxylation, pH/protonation, solvent, and pore environment; compare more than one force-field or computational assumption where feasible; and connect molecular-level outputs to measurable observables such as adsorption energy, loading capacity trends, or desorption behavior. Use published data for validation and clearly distinguish computed predictions from measured values. If the exact chemical structures, surface models, or relevant measurements are not available, do not select this as the lead project.

4. Useful supporting output, usually not the strongest standalone computational paper: systematic evidence map

You could map computational studies of microneedle delivery by model class, needle type, tissue representation, drug/carrier, outputs, and validation strategy. This would help establish whether a more focused modeling gap is real. The 2020 review is a review of microneedle modeling and simulation.(Yadav, 2020)

A stronger evidence map would use a reproducible search protocol, explicit inclusion criteria, a structured extraction dataset, and a concrete quantitative or methodological analysis, then use the map to justify one of directions 1–3.

Recommended project and staged plan

I would start with Direction 2 as a short feasibility phase, then proceed to Direction 1 only if the evidence base supports it. This reduces the risk of spending months building a sophisticated model with no independent data against which to test it.

Scope and novelty audit. Search current literature for dissolving microneedles, mesoporous silica (including hollow variants), skin cancer/melanoma, computational transport, drug-release simulation, and ML. Screen titles/abstracts, then obtain and read full texts of the closest studies. Make a table of what each model includes and excludes. The initial sources here are insufficient to certify novelty.
Data inventory. Extract a pilot set of approximately 20–30 papers (a planning target, not a required sample size) and count usable numeric observations for each outcome. Check whether the observations are comparable and whether at least one study or study family can be held out. If no defensible validation split is possible, stop the ML path rather than inflate performance with random splits.
Minimal baseline. Fit and evaluate a simple physical or statistical baseline before developing a complex model. Lock the study-level split before feature engineering. Report performance by outcome and study, uncertainty, and failure cases.
Mechanistic extension. Add coupled dissolution, silica release, skin transport, and tumor compartment terms only where they are supported by parameter data or sensitivity analysis. Compare complexity against predictive gain.
Reproducibility package. Publish extraction rules, source-level data provenance, code, parameter files, model assumptions, and a clear statement of limitations. A computational study without lab work should be especially explicit about what was not independently measured.

Quality bar for a credible Q1/Q2 submission

Journal quartile and impact factor do not guarantee acceptance or scientific quality; they vary by year and subject category, and should be checked in the journal’s current indexing and metrics before submission. No research design can guarantee a Q1 or Q2 outcome. For your constraints, target a paper with a strong, defensible contribution rather than a journal label first.

A competitive computational manuscript should normally have:

A narrow question and a real decision impact. Make the output useful for choosing formulation or design parameters, not just “we simulated delivery.”
A confirmed gap. Cite the exact limitations in recent primary studies/reviews and show how your design resolves one of them. The present source set is too small to make an exclusivity claim.
Data traceability. Every extracted value should have a paper, figure/table location, units, conditions, and uncertainty or confidence tag.
Verification and validation separated. Verification asks whether the code solves the equations correctly; validation asks whether predictions agree with observations. One is not a substitute for the other.
Independent testing. Split by paper or formulation—not by rows from a shared experiment. Report a simple comparator, uncertainty, and cases where predictions fail.
Sensitivity and robustness. Show which assumptions drive conclusions and whether the recommended design remains useful over plausible parameter ranges.
Reproducibility. Release code, environment/version information, extraction protocol, and analysis scripts. Include negative or inconclusive results where they constrain the claims.
Claims matched to evidence. If no relevant tumor-delivery data exist, describe a model of delivery to a tumor compartment as a hypothesis-generating scenario, not a validated cancer treatment prediction.

Directions I would avoid

ML trained and tested on synthetic data from your own simulator only. That can show that an algorithm emulates its generator, not that it predicts real microneedle behavior.
A generic review of “AI in microneedles.” Without systematic methods, a new dataset, or a specific technical synthesis, it may not make a sufficiently distinct contribution. The 2020 paper is already a review of microneedle modeling and simulation.(Yadav, 2020)
An unnecessarily complex three-dimensional model with many unmeasured parameters. More complexity can create more unsupported assumptions; the review specifically warns that model simplifications and omitted skin/contact behavior can undermine reliability.(Yadav, 2020)
A molecular simulation with no experimental bridge. For your stated goal, calculated molecular properties need to connect to observed loading/release or be framed as a tightly scoped theoretical study.
Promising a high-impact journal as an outcome. You can design for methodological quality and journal fit, but no one can responsibly guarantee quartile, impact factor, or acceptance.

Practical recommendation

Your strongest starting title concept is: “A literature-grounded, uncertainty-aware computational framework for predicting tumor-localized delivery from dissolving microneedles carrying mesoporous-silica drug carriers.” Treat it as a provisional title. First establish the literature gap and the number and quality of extractable data points. If the dataset supports grouped external testing, combine it with a mechanistic model and use ML as a challenger or emulator—not as the paper’s entire novelty. If there are too few relevant data, choose a narrower simulation question with published validation data, or produce a rigorous evidence map and use it to identify a tractable follow-up.

The answer is preliminary because the full-text search retrieved only two relevant accessible papers, and additional PDFs have been requested. In particular, the exact novelty of the silica–dissolving microneedle–skin-cancer combination, current competing ML studies, and suitable target journals remain to be checked against a broader full-text set.

UPLOADED

Uploaded · Ready to open

I uploaded the full text for "A new computational method of modeling and evaluation of dissolving microneedle for drug delivery applications: Extension to theoretical modeling of a novel design of microneedle (array in array) for ", "Studies on drug delivery from dissolving microneedle and its uptake in tissue", "Mathematical modelling of microneedle-mediated transdermal delivery of drug nanocarriers into skin tissue and circulatory system.", "Modelling of dissolving microneedles for transdermal drug delivery: theoretical and experimental aspects", "Modeling of transdermal drug delivery with a microneedle array", "Mechanistic modeling for optimal design of dissolvable microneedle-based patches for transdermal drug delivery", "Modeling of Dissolving Microneedle-Based Transdermal Drug Delivery: Effects of Dynamics of Polymers in Solution.", "Modelling transdermal delivery of high molecular weight drugs from microneedle systems", "Numerical simulation of microneedles' insertion into skin", "Modelling the in-vitro dissolution and release of sumatriptan succinate from polyvinylpyrrolidone-based microneedles", "Mass transfer analysis of transdermal drug delivery using microneedles", "Experimental and mathematical study of the transdermal delivery of sumatriptan succinate from polyvinylpyrrolidone-based microneedles", "Transdermal Drug Delivery by Microneedles: Does Skin Metabolism Matter?" — use it. Use only the abstract for "Modelling nanocarrier-mediated transdermal drug delivery to skin and its retention in tissue using dissolving microneedles", "[Results of surgical treatment of 334 rectal, rectosigmoid and anal canal tumors]". Continue the answer with these decisions.

Updated assessment after reading the uploaded full texts

What changes from my earlier recommendation

Your uploads materially refine the gap assessment. I would withdraw the broad “digital twin combining dissolving microneedles, nanocarriers, skin and systemic compartments” as a novelty claim. A 2024 dissolving-microneedle model already includes skin, blood and tissue compartments with reversible drug exchange, although its authors identify omissions including interstitial flow, metabolism, binding and skin viscoelasticity, and call for stronger validation.(Mondal, 2024) (Mondal, 2024) A 2026 paper’s abstract describes a dissolving-microneedle/nanocarrier model for skin, blood and tissue compartments, reversible tissue uptake and saturable drug binding; it reports a maximum relative percentage error below 0.39% against published data.(Sultana, 2026) Because only the abstract was used, that reported error needs checking in the full paper before it becomes a central comparison.

A separate 2023 full-text model already examines nanocarrier-mediated microneedle transport across realistic skin layers and into blood, with comparisons to experimental depth profiles. Its authors describe the predictions as qualitative, note that many parameters vary across patients and locations, and say that adapting the framework to specific microneedle and nanocarrier types requires additional modeling.(Newell, 2023) (Newell, 2023) The research opportunity is therefore not simply to combine these compartments. It is to test model transferability and uncertainty across drug/polymer systems—or to add a narrowly defined, data-supported material or tumor mechanism that existing models do not include.

The most defensible computational topic now

Recommended: cross-study validation and uncertainty benchmark for dissolving-microneedle delivery models

Provisional title: How transferable are mechanistic models of dissolving microneedle delivery? A literature-grounded benchmark of dissolution, skin permeation and pharmacokinetic predictions.

Research question: When models developed for different dissolving microneedle formulations are evaluated against published data not used in calibration, which model structures and measured inputs best predict (a) needle dissolution/height change, (b) cumulative drug release or skin permeation, and (c) skin or blood exposure?

This is a stronger fit to your no-lab constraint than inventing an unvalidated cancer-delivery simulation. The uploaded literature already includes several distinct modeling and validation settings: experimental dissolution/permeation data for PVP-based sumatriptan formulations; a dissolving-microneedle polymer-physics model for PVP and ceftriaxone; dissolving-microneedle models calibrated to naloxone or levonorgestrel release/plasma data; and models that add tissue uptake or nanocarrier transport.(Ronnander, 2020) (Yadav, 2024) (Peláez, 2023) (Newell, 2023) The 2024 polymer-physics paper specifically notes that its validation used one drug, one polymer and one ex-vivo dataset, and calls for testing additional molecules, polymers, shapes and compositions.(Yadav, 2024) That statement gives a direct basis for a validation/transferability study.

Important scope rule: Do not force every study into one pooled dataset. Treat release fraction, microneedle height reduction, skin deposition/permeation, plasma concentration and tissue concentration as separate outcomes. Compare studies only where the endpoint, experimental conditions and units are sufficiently compatible. If compatible data are sparse, publish a structured benchmark of separate endpoint families rather than report a misleading pooled score.

Proposed methods:

Create a provenance-rich dataset. Extract time-series points and formulation/model parameters from full-text papers, tables and plots. Record drug, polymer, geometry, loading, skin source, assay, time, units, model equations, fitted versus independently measured parameters, and figure/table location. Mark values digitized from plots and preserve extraction uncertainty.
Reconstruct a small number of model families. Start with a simple empirical release model, then compare it with a dissolution/transport model and—only where data support it—a model including skin or systemic compartments. The uploaded papers provide examples of those model types, from dissolution and drug transport in conical needles to polymer disentanglement and multi-compartment uptake.(Kim, 2015) (Yadav, 2024) (Mondal, 2024)
Evaluate by study, not by individual time point. Keep all points from the same experiment/formulation together. Use leave-one-study-out or grouped validation; calibrate on some studies and predict another formulation or study. Randomly splitting points from a single release curve would leak information and overstate generalization.
Quantify uncertainty and identifiability. Use parameter ranges from the papers, sensitivity analysis and uncertainty propagation. Test whether release curves alone identify dissolution and diffusion parameters separately, or whether needle-height and permeation measurements are also needed. Report prediction intervals and failures, not only a best-fit curve.
Make a decision-relevant result. Identify which model is adequate for which endpoint and when additional model complexity improves held-out prediction. Release code, data, extraction rules and model assumptions.

The novelty would be the independent cross-study test, not a new equation for its own sake. Before committing, run a short data audit. If few studies supply comparable numeric curves or the papers do not permit independent testing, narrow the question to parameter identifiability/model comparison for the best-supported endpoint. The submitted paper must not describe an unvalidated literature-derived model as a predictive clinical tool.

A second, higher-risk path: material-specific silica or skin-tumor extension

Your hollow mesoporous silica and skin-cancer expertise could support a subsequent extension: compare how plausible silica-carrier release and transport parameters alter predicted drug exposure in a specified skin-tumor compartment, while accounting for exposure in non-tumor skin and systemic compartments. However, the 13 uploaded full texts do not establish a hollow-mesoporous-silica/melanoma model or provide direct validation data for that combined system. The 2026 nanocarrier paper’s abstract is relevant to the general model class, but it does not establish silica-specific or melanoma-specific validation.(Sultana, 2026) Thus, the exact silica–melanoma gap remains unverified, not a proven “first” opportunity.

For a credible purely computational paper, do not just insert a tumor compartment and choose arbitrary tumor uptake constants. First locate published quantitative data for the specific drug/carrier, silica loading/release, skin/tumor transport and tumor retention. If these inputs are absent, keep the cancer application explicitly as a scenario analysis and avoid claims about treatment efficacy. A more defensible option is to build the model benchmark first, then add a transparent silica parameterization only if the evidence audit yields enough independently reported data.

Where machine learning fits—and where it does not

I would not make ML the main novelty at this stage. The uploaded studies are predominantly mechanistic or numerical models, and several already calibrate against experimental data or conduct sensitivity/optimization analyses.(Peláez, 2023) (Ronnander, 2020) (Kong, 2011) The relevant challenge is heterogeneous, study-specific data and establishing external predictive validity; an ML model trained on a few unrelated release curves would be at high risk of overfitting. Use ML only if the data audit reveals enough distinct studies and formulations for a study-grouped test. Then compare it against mechanistic and simple statistical baselines, with grouped validation and uncertainty intervals. Otherwise, Bayesian parameter estimation, global sensitivity, model comparison, or reduced-order surrogates for a validated mechanistic model are more defensible computational contributions.

How the 13 uploaded full texts affect the gap assessment

Uploaded source	How it informs the decision
2020 array-in-array dissolving-microneedle simulation	Dissolving-needle dissolution/transport was compared with corneal delivery experiments, then an array-in-array geometry was modeled; this confirms that geometry-only novelty is already occupied.(Zoudani, 2020)
2024 dissolving-needle model with blood/tissue uptake	Adds blood/tissue uptake to a single-cone dissolving-needle model; its authors call out omitted biology/mechanics and request further validation.(Mondal, 2024) (Mondal, 2024)
2023 nanocarrier transport model	Models nanocarriers across skin layers and blood and compares depth profiles with experiments, while noting qualitative prediction and the need for specific formulation/needle adaptation.(Newell, 2023) (Newell, 2023)
2015 single-cone dissolving-needle model	Provides a dissolving-needle/drug-in-skin model and parameter recovery from needle-height data; a new single-cone model alone would be incremental.(Kim, 2015)
2006 microneedle-array flow/transport model	Already couples flow and drug transport in an array model, illustrating the long history of mechanistic MN simulations.(Lv, 2006)
2023 mechanistic patch-design optimization model	Calibrates release/PK models to naloxone and levonorgestrel data, uses global sensitivity and optimizes design; its stated limitation includes unmodeled nonspecific binding/degradation.(Peláez, 2023) (Peláez, 2023)
2024 polymer-physics dissolving-needle model	Adds polymer physics and an annular interstitial-fluid gap for PVP/ceftriaxone; its authors explicitly seek validation across more drugs, polymers and compositions.(Yadav, 2024) (Yadav, 2024)
2007 high-molecular-weight drug model	Established parameter analysis and scaling relationships for drug delivery from MN systems; generic geometry/parameter sweeps are not sufficient novelty by themselves.(Al-Qallaf, 2007)
2011 finite-element insertion mechanics study	Provides multilayer finite-element insertion mechanics and compares insertion force/deformation with reported experiments; could inform a coupled mechanical submodel, not drug-release novelty.(Kong, 2011)
2018 sumatriptan release model	Models PVP-based sumatriptan dissolution and skin transport and validates against minipig-skin in-vitro data.(Ronnander, 2018)
2009 microneedle mass-transfer thesis	Covers modeling, optimization, skin thickness and metabolism across multiple MN designs; useful as a methods source, but much of it is older and broader than the DMN benchmark question.(Al‐Qallaf, 2009)
2019 sumatriptan experimental/modeling study	Adds three PVP formulations, minipig skin and OCT-related evidence to release/permeation modeling; valuable data for the benchmark, but related to the 2018 sumatriptan modeling paper, so check whether the datasets overlap before counting them independently.(Ronnander, 2020)
2009 skin-metabolism model	Models verapamil and finds a smaller metabolism effect with microneedles than conventional patches in that modeled case; it does not establish that metabolism is negligible for every drug or carrier.(Al‐Qallaf, 2009) (Al‐Qallaf, 2009)

UPLOADED

Uploaded · Ready to open

I uploaded the full text for "Enhanced Transdermal Delivery by Combined Application of Dissolving Microneedle Patch on Serum-Treated Skin", "Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: Bubble and pedestal microneedle designs", "Characterization method for calculating diffusion coefficient of drug from polylactic acid (PLA) microneedles into the skin", "Dissolving microneedles: an advanced approach for transdermal drug delivery", "Dissolving microneedles for transdermal drug delivery in cancer immunotherapy.", "Dissolving microneedles: Applications and growing therapeutic potential" — use it. Use only the abstract for "Dissolving microneedles for drug delivery", "The potential use of microneedles as an alternative method for skin cancer treatment", "Dissolving Microneedles as In Situ Chemical Reaction Chambers: from Design Strategies to Versatile Biomedical Applications". Continue the answer with these decisions.

Update: the new cancer and materials sources sharpen the topic

These additions change the application focus, but not the caution about novelty. The broad idea “dissolving microneedles plus nanocarriers for cancer” is no longer a defensible gap claim: a 2024 cancer-immunotherapy review describes mesoporous silica nanoparticles incorporated into a microneedle cancer-vaccine system, alongside other melanoma and cancer immunotherapy microneedle approaches.(Xiang, 2024) A 2022 review also summarizes dissolving-microneedle melanoma systems using STAT3 siRNA, chemotherapy, and photothermal combinations.(Sartawi, 2022) A 2023 mechanistic model already examines nanocarrier transport from microneedles through skin and into blood; its authors note that adapting the framework to a specific carrier or needle type requires further work.(Newell, 2023) (Newell, 2023)

What remains not established by these sources is a validated computational model specifically for hollow mesoporous silica carriers delivering a specified melanoma therapy. The cancer-immunotherapy review says that clinical efficacy is not yet well confirmed and identifies human biodistribution, release kinetics and therapeutic outcomes as areas needing more attention.(Xiang, 2024) This points to a more meaningful gap than simply adding another carrier or compartment: connecting microneedle formulation and local release to tumor-localized exposure and therapeutic response, while representing uncertainty and testing predictions against published preclinical data.

Updated topic options

Best cancer fit, conditional on data availability

Provisional title: From dissolving-microneedle design to melanoma response: an uncertainty-aware computational model of local immunotherapy exposure and outcome.

Question: Can a mechanistic model, parameterized from published studies, predict how dissolving-microneedle release and skin/tumor transport affect local drug exposure, systemic escape and tumor-response trajectories for one defined melanoma therapy?

Proposed computational study: choose one therapy class with several quantitative preclinical reports—for example, a local checkpoint-inhibitor/adjuvant combination or a melanoma vaccine. Couple (1) patch dissolution and drug release, (2) transport through skin into a local tumor compartment, (3) local retention and systemic loss, and (4) a deliberately simple exposure–response relation for tumor growth. Estimate parameters from one set of published studies and test against a separate study or formulation. Use uncertainty and sensitivity analysis to identify whether release rate, local retention, tumor uptake or systemic clearance dominates the predicted response.

Do not start with several cancers, drugs, immune mechanisms and nanocarriers at once. The 2024 review covers cancer vaccines, checkpoint inhibitors and cell therapies.(Xiang, 2024)

These modalities do not share one outcome class, so I recommend modeling one defined therapy and using grouped external testing. The review’s statement about unmet human distribution and outcome data motivates the translational question, but a model fitted only to mouse/preclinical observations must not be presented as a validated human efficacy predictor.(Xiang, 2024)

This option is conditional: first acquire and inspect full texts of the primary melanoma studies cited in the reviews and determine whether they report comparable release, tissue-distribution or tumor-growth time series. The abstracts and review summaries alone are not enough to reconstruct or validate this model. If the primary papers do not provide usable numeric data, do not fill the gaps with arbitrary values; use the cross-study modeling benchmark from the previous answer instead.

Strongest fit to your silica background, but not yet a confirmed novelty

A silica-focused extension could compare predicted release and local exposure for a conventional mesoporous-silica carrier versus a hollow mesoporous-silica design inside dissolving microneedles. However, the 2024 review already describes an MSN-containing microneedle vaccine, and it does not establish that the particles were hollow or that a computational design comparison was absent.(Xiang, 2024) Therefore, frame “hollow” as a specific hypothesis to investigate—not as an established first. The model needs carrier-specific published loading/release and transport measurements; otherwise it is a scenario analysis, not a predictive study. The exact hollow-silica/melanoma gap remains unverified in this source set.

Lower-risk methodological direction

Retain the previous recommendation—a cross-study validation and uncertainty benchmark for dissolving-microneedle models—as the fallback with the clearest no-lab route. The new PLA study gives a quantitative method for estimating drug diffusion from microneedles into porcine skin using fluorescence calibration and constant- versus limited-source diffusion models.(Wu, 2020) The bubble/pedestal study shows that drug localization and insertion geometry can materially alter delivery: its abstract reports about 80% delivery within 10 minutes for tip-localized model drug versus 20% for nonlocalized drug.(Chu, 2010) Those studies can inform benchmark variables and boundary conditions, but their dyes, polymers and skin assays should not be treated as interchangeable with silica nanocarriers or melanoma therapeutics.

How the new uploads refine the earlier plan

A combined serum-plus-DMN application is already experimentally demonstrated for hyperpigmentation. The study reports that DMN-created channels delivered a pre-applied serum into skin and that the combined approach outperformed serum alone on melanin-related outcomes in its human study.(Kim, 2017) This is useful precedent for modeling combined topical/patch exposure, but it is not cancer evidence.
Drug localization and insertion geometry are established design variables. The bubble/pedestal study experimentally explored tip-localized loading, increased dose capacity and more complete insertion.(Chu, 2010) Do not claim a novel project solely on optimizing tip loading or needle elevation.
Measured tissue diffusion can anchor a transport model. The PLA study calibrated fluorescence intensity to concentration and inferred a rhodamine-B diffusion coefficient from microneedles into porcine dermis.(Wu, 2020) This supports a parameter-measurement approach; it does not supply a transferable coefficient for an anticancer payload or silica particle.
Cancer and melanoma microneedle applications have already been broadly reviewed. The 2022 review covers cancer among multiple DMN application areas and summarizes melanoma-focused examples.(Sartawi, 2022) (Sartawi, 2022)

A new broad “review of microneedles in cancer” would need a distinctly systematic and quantitative contribution to avoid repeating existing reviews.

Responsive or reaction-based microneedles are also an existing concept. The abstract-only review on dissolving microneedles as in-situ reaction chambers discusses local prodrug activation and other skin reactions.(Tian, 2025)

“Stimuli-responsive” or “reaction-chamber” alone is not a sufficient novelty claim.

A skin-cancer proof-of-principle exists, but evidence is limited to the abstract here. The abstract-only cancer-treatment record describes TNF-α-loaded dissolving microneedles and porcine-skin diffusion, with preliminary enhanced distribution versus a non-needle control.(Loizidou, 2019) It does not establish clinical melanoma efficacy.
Two general DMN reviews are not primary modeling evidence. The 2025 review discusses applications, manufacturing and insertion variability, while the 2022 review covers clinical/commercial directions.(Tandon, 2025) (Sartawi, 2022) Use them to map the field, not to claim quantitative model validation.
A two-speed release architecture is already described in the abstract-only drug-delivery paper. It reports a double-layered biodegradable microneedle system with two release times in vitro.(Zhuang, 2017) A new “sequential release” topic would need a more specific, validated contribution.

Recommendation

If you want the new paper to remain close to skin cancer, pursue the focused exposure–response model only after verifying that primary melanoma microneedle studies provide sufficient quantitative data for independent testing. If you want the most tractable computational paper without lab work, retain the model benchmark and make cancer a carefully bounded application case. In either route, mesoporous silica in microneedle cancer delivery is not wholly unexplored, and the hollow-silica-specific claim requires a separate novelty search and primary-source check.

I read all six newly uploaded full texts. I used only abstracts for the three additional records you specified: Dissolving microneedles for drug delivery, The potential use of microneedles as an alternative method for skin cancer treatment, and Dissolving Microneedles as In Situ Chemical Reaction Chambers. The full-text limits for those three are intentional; their claims above are explicitly scoped to the abstracts.

Save

Modelling nanocarrier-mediated transdermal drug delivery to skin and its retention in tissue using dissolving microneedles.pdf

UPLOADED

Uploaded · Ready to open

I uploaded the full text for "Modelling nanocarrier-mediated transdermal drug delivery to skin and its retention in tissue using dissolving microneedles" — use it. Continue the answer with these decisions.

Updated recommendation after reading the full 2026 paper

This full text changes the gap assessment in an important way. The 2026 study is not merely a broad nanocarrier paper: it models nanocarrier-encapsulated drug released from a dissolving microneedle, with drug and carrier tracked through skin, blood and tissue compartments, reversible blood–tissue exchange, and reversible saturable binding in tissue.(Sultana, 2026) It varies dissolution, carrier loading, release, elimination and binding parameters, and reports drug exposure and receptor occupancy.(Sultana, 2026) So a paper framed as the first model combining dissolving microneedles, nanocarriers, tissue retention and blood/tissue compartments would be inaccurate.

What the full text actually leaves open

The reported maximum error below 0.39% needs careful interpretation. In the paper’s comparison, the authors first reduce their model to the assumptions of an earlier dissolving-microneedle model and compare predicted skin concentrations with that model’s results.(Sultana, 2026) (Sultana, 2026) This is useful model-to-model consistency checking, but it does not independently validate the full nanocarrier-plus-binding model against a new experimental release, skin-distribution or tumor-response dataset. The paper also declares that no animal or human subjects were used.(Sultana, 2026)

The model is a temporal compartment model with a monolayer skin representation; its authors list important simplifications: isotropic dissolution and constant needle angle, omitted skin deformation, and no spatially resolved delivery or phagocytosis.(Sultana, 2026) (Sultana, 2026) Its parameter table combines values from several prior sources and includes estimated transfer parameters, so uncertainty and identifiability are material issues for reproducing or extending its predictions.(Sultana, 2026) (Sultana, 2026)

The paper does not specify a hollow mesoporous silica formulation, melanoma therapy, tumor compartment or tumor-response equation. It mentions targeted cancer therapy as a possible future application, not as a modeled or validated use case.(Sultana, 2026) The hollow-silica/melanoma gap therefore remains unconfirmed, while the broader DMN–nanocarrier–tissue model gap is now closed.

Revised best topic

Provisional title: Independent validation and formulation-specific testing of a dissolving-microneedle nanocarrier retention model: a literature-grounded computational study.

Research question: Does the published compartment model predict measured release, skin concentration and tissue retention when tested against independent published datasets—not just against a reduced prior model—and which uncertain parameters most affect those predictions?

Proposed no-lab workflow:

Reproduce the 2026 model from its equations and parameter table; document any ambiguities and check mass balance and numerical convergence.
Extract measured time-series data from primary studies for the same endpoint and comparable conditions. Keep release, skin diffusion, blood concentration and tissue retention as distinct outcomes; do not pool incompatible assays or compounds.
Separate calibration from testing by study or formulation. Fit on one set of studies and hold out complete papers or formulations. A random split of points from the same curve is not independent validation.
Propagate reported parameter ranges and plausible uncertainty in parameters borrowed from other models. Test identifiability: determine whether the available measurements can distinguish microneedle dissolution, nanocarrier release, skin loss and tissue binding.
Compare the original compartment formulation with one carefully justified extension—such as spatially resolved skin/tumor transport—only if the data can constrain it. Report prediction intervals, failure cases and the conditions where the model should not be used.

This is now a stronger and more precise computational gap than proposing another generic coupled model. The paper’s data-availability statement says its study data are included in the article, so reproducing its calculations is plausible.(Sultana, 2026) The paper’s comparison is with a reduced prior model rather than an independent experiment, so external empirical validation would require suitable primary-study measurements.(Sultana, 2026) (Sultana, 2026)

If those measurements are too sparse, narrow the paper to a transparent reproducibility, sensitivity and parameter-identifiability analysis, and do not claim predictive validation.

How this changes the cancer and silica route

A melanoma extension is still a reasonable second-stage application, not a novelty claim on its own. It would need a cancer-specific target compartment and an exposure–response relationship fitted and tested against published melanoma microneedle data. The 2026 model’s equations describe generic skin, blood and tissue compartments, with binding in the tissue compartment.(Sultana, 2026) The authors mention targeted cancer therapy as a possible future application.(Sultana, 2026)

For hollow mesoporous silica, specify what is genuinely new—such as carrier-specific release/partition parameters or tumor-localized retention—and support those inputs with independent published measurements. Since prior uploaded sources already describe mesoporous-silica nanoparticles in a microneedle cancer-vaccine context, novelty cannot rest simply on “silica plus microneedles plus cancer.”(Xiang, 2024) The hollow architecture and its quantitative behavior would need to be verified in primary sources before claiming a gap.

Bottom line: I would now prioritize independent empirical validation and uncertainty analysis of the 2026 model, with melanoma/hollow silica as a tightly bounded extension only if the literature supplies usable data. This is feasible without new lab work, but it cannot guarantee Q1/Q2 acceptance; the value will depend on genuinely independent tests, reproducible code/data extraction and a clear limit on what the model predicts.

Save

i dont need general and vague topics. i need specific literature gaps that can either generate a q1 or q2 paper or is directly a topic for q1 or q2

Specific, publishable gaps after the full-text review

You are right: “build a better digital twin” is too vague. After reading the full 2026 paper, I would not recommend another generic dissolving-microneedle/nanocarrier compartment model. That paper already models carrier release from dissolving microneedles, skin–blood–tissue transport, reversible uptake and saturable tissue binding.(Sultana, 2026) The authors also vary drug loading, dissolution, carrier release and binding parameters.(Sultana, 2026)

First choice: spatially resolved, independently tested extension of the 2026 model

Paper-ready title: Does spatial resolution change predicted tumor exposure from nanocarrier-loaded dissolving microneedles? Independent validation and uncertainty analysis of a skin-to-tumor transport model.

Specific gap: The 2026 model is temporal and compartmental, uses a monolayer skin representation, and assumes uniform/isotropic needle dissolution. Its authors explicitly say that spatial effects, phagocytosis and insertion-related skin deformation are not represented.(Sultana, 2026) (Sultana, 2026) Their reported error below 0.39% comes from reducing their equations to compare with an earlier model’s predicted skin concentrations; it is not an independent experimental test of the complete nanocarrier/binding model.(Sultana, 2026) (Sultana, 2026) A separate tissue-scale microneedle/nanocarrier model does represent anatomically distinct skin layers and compares predictions with experimental concentration profiles, but it is not a dissolving-microneedle-specific model.(Newell, 2023)

Research question: For the same drug, carrier and dose, does replacing the single-skin-compartment representation with spatial skin layers change predicted target-site exposure, retention time and systemic escape enough to change the preferred microneedle design?

Proposed computational study:

Reproduce the 2026 compartment model and its reported comparisons before modifying it. Treat that as code/model verification, not empirical validation.
Build a spatial extension with viable epidermis, papillary dermis and reticular dermis, plus a clearly defined local target-tissue compartment. Add a lymphatic/systemic sink only if the independent data can constrain it. Retain the published dissolution and nanocarrier-release equations initially; do not add every possible biological process at once.
Extract one compatible primary-data family for calibration and hold out complete studies or formulations for testing. Compare predicted concentration-versus-depth or time-course data, not just fitted release curves. The existing spatial model’s comparison with experimental skin profiles is a methodological precedent, not validation for your silica formulation.(Newell, 2023)
Run uncertainty and global sensitivity analyses on dissolution rate, carrier release, tissue partition/uptake, binding and clearance. Report prediction intervals and whether rankings of designs remain stable across parameter ranges.
Add melanoma as a scenario application only after the transport model passes an external test. The uploaded cancer-immunotherapy review identifies missing human biodistribution, release-kinetic and outcome evidence, so preclinical data must not be presented as validated human efficacy.(Xiang, 2024)

Why this can be a serious paper: It tests a consequential modeling assumption—well-mixed compartments versus spatial transport—and asks whether that assumption alters a design decision. It can be done without new experiments if the relevant papers provide digitizable, comparable observations. If the data audit finds no independent concentration profiles for the selected carrier/drug class, the cancer extension is not yet a validated study; narrow the paper to model reproduction, identifiability and uncertainty instead.

Second choice: an exact parameter-identifiability paper

Paper-ready title: What can published dissolving-microneedle data actually identify? Structural and practical identifiability of dissolution, nanocarrier release and tissue-binding parameters.

Specific gap: The 2026 model uses parameters assembled from multiple sources, including estimated carrier-transfer and tissue-binding values.(Sultana, 2026) (Sultana, 2026) Its outputs are sensitive to blood–tissue transfer parameters: the paper reports substantial AUC changes when those parameters are varied.(Sultana, 2026) But sensitivity alone does not establish that those parameters can be separately estimated from the available observations.

Question and design: Using the published equations and digitized time courses, determine whether needle-height/dissolution data alone can identify dissolution rate; whether release curves additionally identify nanocarrier release; and whether skin, blood and tissue concentration measurements are needed to identify clearance, transfer and binding separately. Use profile likelihood or Bayesian posterior analysis, synthetic recovery tests, and study-level holdouts. Compare practical identifiability under (a) release-only, (b) release plus skin concentration, and (c) multi-compartment observations. Do not claim the synthetic recovery is biological validation: it tests the estimator under the assumed model.

This is more tractable than a cancer-response model and can yield a concrete design recommendation about which measurements future studies must report. Its publication ceiling depends on a strong, reproducible analysis and a clear result—not on the phrase “AI” or on a large parameter sweep.

Third choice: hollow-mesoporous-silica melanoma model—only after a data gate

Paper-ready title: Formulation-specific modeling of hollow mesoporous silica release from dissolving microneedles for localized melanoma therapy: predicted tumor retention versus systemic escape.

Specific gap: The 2026 equations treat nanocarriers through generic release, transport and binding parameters; they do not model a specified silica architecture, melanoma pharmacology or tumor response.(Sultana, 2026) A cancer-immunotherapy review does report mesoporous silica nanoparticles in a microneedle cancer-vaccine system, so “silica plus microneedles plus cancer” is not itself novel.(Xiang, 2024) The unresolved question is whether the hollow pore architecture produces a measurable release/retention behavior that changes tumor exposure after microneedle delivery. That exact gap is not established by the uploaded papers.

Go/no-go requirement: Before building this model, find primary full-text studies reporting quantitative loading/release and skin or tumor-distribution data for the same hollow-silica formulation or a close enough analogue to justify parameter ranges. If no such independent data exist, do not label the output predictive or clinically optimized; use it only as a hypothesis-generating sensitivity study. This route has the strongest materials fit but the highest data risk.

My direct recommendation

Prioritize Choice 1, with Choice 2 as the fallback if the data audit fails. Do not submit another generic compartment model, and do not claim a validated melanoma/HMSN digital twin until the paper has an independent empirical test. A rigorous computational-only study can be Q1/Q2 material, but no topic can guarantee a quartile or acceptance; the deciding features here are independent validation, explicit uncertainty, reproducible code/data, and a narrow result that changes a design decision.

Follow-up

Save

Citation Lists

Prateek Ranjan Yadav; Tao Han; Ololade Olatunji; Sudip K Pattanayek; Diganta Bhusan Das · 2020 · Pharmaceutics

Tanmoy Bhuimali; Sarifuddin; Diganta Bhusan Das; Prashanta Kumar Mandal · 2025 · Pharmaceutics

X Q Kong; P Zhou; C W Wu · 2011 · Computer methods in biomechanics and biomedical engineering

Suggested next steps

Run a sensitivity analysis

Turn this into a report

Analyze an uploaded PDF

Edit the draft

Export the extraction table

TRY:

Uploaded source

How it informs the decision

2020 array-in-array dissolving-microneedle simulation

Dissolving-needle dissolution/transport was compared with corneal delivery experiments, then an array-in-array geometry was modeled; this confirms that geometry-only novelty is already occupied.(Zoudani, 2020)

2024 dissolving-needle model with blood/tissue uptake

Adds blood/tissue uptake to a single-cone dissolving-needle model; its authors call out omitted biology/mechanics and request further validation.(Mondal, 2024) (Mondal, 2024)

2023 nanocarrier transport model

Models nanocarriers across skin layers and blood and compares depth profiles with experiments, while noting qualitative prediction and the need for specific formulation/needle adaptation.(Newell, 2023) (Newell, 2023)

2015 single-cone dissolving-needle model

Provides a dissolving-needle/drug-in-skin model and parameter recovery from needle-height data; a new single-cone model alone would be incremental.(Kim, 2015)

2006 microneedle-array flow/transport model

Already couples flow and drug transport in an array model, illustrating the long history of mechanistic MN simulations.(Lv, 2006)

2023 mechanistic patch-design optimization model

Calibrates release/PK models to naloxone and levonorgestrel data, uses global sensitivity and optimizes design; its stated limitation includes unmodeled nonspecific binding/degradation.(Peláez, 2023) (Peláez, 2023)

2024 polymer-physics dissolving-needle model

Adds polymer physics and an annular interstitial-fluid gap for PVP/ceftriaxone; its authors explicitly seek validation across more drugs, polymers and compositions.(Yadav, 2024) (Yadav, 2024)

2007 high-molecular-weight drug model

Established parameter analysis and scaling relationships for drug delivery from MN systems; generic geometry/parameter sweeps are not sufficient novelty by themselves.(Al-Qallaf, 2007)

2011 finite-element insertion mechanics study

Provides multilayer finite-element insertion mechanics and compares insertion force/deformation with reported experiments; could inform a coupled mechanical submodel, not drug-release novelty.(Kong, 2011)

2018 sumatriptan release model

Models PVP-based sumatriptan dissolution and skin transport and validates against minipig-skin in-vitro data.(Ronnander, 2018)

2009 microneedle mass-transfer thesis

Covers modeling, optimization, skin thickness and metabolism across multiple MN designs; useful as a methods source, but much of it is older and broader than the DMN benchmark question.(Al‐Qallaf, 2009)

2019 sumatriptan experimental/modeling study

Adds three PVP formulations, minipig skin and OCT-related evidence to release/permeation modeling; valuable data for the benchmark, but related to the 2018 sumatriptan modeling paper, so check whether the datasets overlap before counting them independently.(Ronnander, 2020)

2009 skin-metabolism model

Models verapamil and finds a smaller metabolism effect with microneedles than conventional patches in that modeled case; it does not establish that metabolism is negligible for every drug or carrier.(Al‐Qallaf, 2009) (Al‐Qallaf, 2009)